EDENTREE ASSET MANAGEMENT Ltd Buys Shares of 38,800 IQVIA Holdings Inc. $IQV

EDENTREE ASSET MANAGEMENT Ltd purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 38,800 shares of the medical research company’s stock, valued at approximately $7,368,000. IQVIA makes up about 1.8% of EDENTREE ASSET MANAGEMENT Ltd’s investment portfolio, making the stock its 19th biggest holding.

Several other large investors have also recently added to or reduced their stakes in the stock. Physician Wealth Advisors Inc. boosted its stake in shares of IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares during the period. Westside Investment Management Inc. raised its holdings in shares of IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after acquiring an additional 101 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new stake in IQVIA during the third quarter valued at $36,000. Root Financial Partners LLC acquired a new position in IQVIA in the 3rd quarter worth about $43,000. Finally, Hantz Financial Services Inc. raised its stake in shares of IQVIA by 92.0% during the 3rd quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company’s stock worth $46,000 after purchasing an additional 115 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. BMO Capital Markets set a $250.00 price objective on IQVIA in a report on Friday, February 6th. Morgan Stanley set a $240.00 price target on shares of IQVIA in a research note on Wednesday, February 11th. Evercore restated an “outperform” rating and set a $225.00 price target on shares of IQVIA in a report on Thursday, February 5th. TD Cowen upped their price objective on shares of IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a report on Thursday, January 22nd. Finally, Mizuho set a $266.00 target price on IQVIA in a report on Friday, January 9th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average target price of $235.20.

IQVIA Stock Performance

Shares of IQV opened at $165.63 on Friday. The company has a market capitalization of $28.11 billion, a PE ratio of 21.07, a price-to-earnings-growth ratio of 1.59 and a beta of 1.37. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.70. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company’s fifty day moving average price is $217.61 and its 200 day moving average price is $208.44.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.